Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AST-301 Adjuvant Vaccine in HER2-Low Breast Cancer
NCT05163223Phase 2Terminated
- Sponsor
- Aston Sci
- Start
- Feb 2022
- Primary completion
- May 2024
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in breast cancer comparing AST-301 + Chemo with Placebo + Chemo (2 arms). Primary endpoint: invasive Disease Free Survival rate at 2 years. Started Feb 2022; status: terminated.
02
Drugs
AST-301
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05163223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05163223.